Benzinga
España
Italia
대한민국
日本
Français
My Account
Login
SPY
768.80
0.5%
QQQ
722.02
-
BTC/USD
64095.49
0.5963%
DIA
533.66
0.1%
GLD
402.85
0.65%
TLT
81.26
0.11%
Get Benzinga Pro
Data & APIs
Events
Premarket
Advertise
Contribute
España
Italia
대한민국
日本
Français
Login
Register
Benzinga
Premium Services
Benzinga Edge
Benzinga Pro
Benzinga Research
Benzinga APIs
Financial News
Financial News
Large Cap Stocks
Small-Cap Stocks
Insider Trades
Earnings
Technology
AI News
Personal Finance
ETF News
Crypto News
Dividend News
Latest Rumors
Latest Offerings News
Investment Ideas
Investment Ideas
Stock of the Day
Stock Whisper Index
Analyst Ratings
Analyst Color
Financial Advisors
Government Trades
Trading Ideas
Stock Screener
Markets
Markets
Premarket Movers
After Hours
Options
ETFs
Commodities
Prediction Markets
Private Markets
Bonds
Futures
Forex
Top Stocks
Top Stocks
Apple (AAPL)
Tesla (TSLA)
Amazon (AMZN)
Nvidia (NVDA)
Alphabet (GOOGL)
Meta Platforms (META)
Microsoft (MSFT)
StreetTracks Gold Shares (GLD)
IBIT Bitcoin Trust (IBIT)
Top Value Stocks
Top Momentum Stocks
Top Growth Stocks
Top Quality Stocks
Learn
Learn
Investing Guides
Personal Finance
Mortgages
Best Credit Cards
Best Dividend Stocks
Best Swing Trade Stocks
Investment Ideas
Investment Ideas
Stock of the Day
Stock Whisper Index
Analyst Ratings
Analyst Color
Financial Advisors
Government Trades
Trading Ideas
Stock Screener
Markets
Markets
Premarket Movers
After Hours
Options
ETFs
Commodities
Prediction Markets
Private Markets
Bonds
Futures
Forex
Top Stocks
Top Stocks
Apple (AAPL)
Tesla (TSLA)
Amazon (AMZN)
Nvidia (NVDA)
Alphabet (GOOGL)
Meta Platforms (META)
Microsoft (MSFT)
StreetTracks Gold Shares (GLD)
IBIT Bitcoin Trust (IBIT)
Top Value Stocks
Top Momentum Stocks
Top Growth Stocks
Top Quality Stocks
Learn
Learn
Investing Guides
Personal Finance
Mortgages
Best Credit Cards
Best Dividend Stocks
Best Swing Trade Stocks
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
Events Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
Unusual Options Activity Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Perfect Stock Portfolio
Easy Income Portfolio
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Options Profit Calculator
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Covered Call Calculator
Cash-Secured Put Calculator
Long Call Calculator
Long Put Calculator
Screeners
Stock Screener
Top Momentum Stocks
Top Quality Stocks
Top Value Stocks
Top Growth Stocks
Compare Best Stocks
Best Momentum Stocks
Best Quality Stocks
Best Value Stocks
Best Growth Stocks
Markets
SPY
768.80
0.5%
QQQ
722.02
-
BTC/USD
64095.49
0.5963%
DIA
533.66
0.1%
GLD
402.85
0.65%
TLT
81.26
0.11%
Merck & Co Inc
MRK
NYSE
Watchlist
Get Report
Trade with Public
Get Report
Trade with Public
$135.97
0.13
0.1%
At close: Aug 14, 5:00 PM EST
$136.08
0.24
0.18%
Pre-Market: 5:09 AM EST
Get Report
Overview
News
Earnings Forecast
Events
Price Targets
Financials
Sentiment
Ownership
Dividends
Compare
Options
Stock Report
Merck & Co Financials
Merck & Co (MRK) financial statements — income, revenue, gross margin and key metrics.
Earnings & Guidance News
Why Merck Just Slashed Its Profit Outlook By Nearly 50%
Merck cuts FY2026 adjusted EPS outlook nearly in half to $2.66-$2.76, citing $2.43/share in charges from its Terns acquisition.
Vandana Singh
PRO
Merck & Co Lowers FY2026 Adj EPS Guidance from $5.04-$5.16 to $2.66-$2.76 vs $2.76 Est; Raises FY2026 Sales Guidance from $65.800B-$67.000B to $66.300B-$67.300B vs $66.802B Est
Merck & Co (NYSE:MRK) lowers FY2026 Adj EPS guidance from $5.04-$5.16 to $2.66-$2.76 vs $2.76 analyst estimate. Raises FY2026 sales outlook from $65.800 billion-$67.000 billion to $66.300 billion-$67.300 billion vs
Benzinga Newsdesk
PRO
Merck & Co Q2 Adj. EPS $(0.13) Beats $(0.27) Estimate, Sales $16.607B Beat $16.356B Estimate
Merck & Co (NYSE:MRK) reported quarterly losses of $(0.13) per share which beat the analyst consensus estimate of $(0.27) by 51.85 percent. This is a 106.1 percent decrease over earnings of $2.13 per share from the
Benzinga Newsdesk
Tempus AI's Big Pharma AI Partnerships Are Getting Bigger And Stickier
Tempus AI (TEM) Q1 results: Revenue up 36.1% to $348.1M, beating estimates. TEM raises 2026 outlook amid strong AI & diagnostic demand.
Lekha Gupta
S&P 500's Best‑Kept Secret: Why Healthcare Could Be 2026's Breakout Winner
AI‑powered drug discovery, strong earnings upgrades, and rising institutional flows show why healthcare may shift from 2026 laggard to breakout S&P 500 growth story.
Stjepan Kalinic
Merck Swings To Quarterly Loss On Cidara Deal
Merck Q1 2026 results show oncology-led growth, vaccine weakness, and raised guidance after beating sales and loss estimates.
Vandana Singh
Privacy Manager